[New horizons of ED-71 (vitamin D analog)].
ED-71 is a vitamin D analog which was designed to have prominent effect on bone tissue. ED-71 has a hydroxypropoxy residue at the 2beta position and binds to the vitamin D receptor with one eighth affinity compared with original 1alpha,25-dihydroxyvitamin D(3). ED-71 has a longer half life than 1alpha,25-dihydroxyvitamin D(3) due to twice as high affinity with vitamin D binding protein in plasma. The result of late phase II study revealed ED-71 increased bone mass in a dose-dependent manner even under sufficient vitamin D supplementation, which accelerates the clinical use of ED-71.
Shionoiri
Atsushi
A
Department of Geriatric Medicine, Graduate School of Medicin, The University of Tokyo.
D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002117:Calcitriol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006207:Half-Life; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D014807:Vitamin D / Q000031:analogs & derivatives
D050071:Bone Density Conservation Agents; D014807:Vitamin D; D002117:Calcitriol; C547512:eldecalcitol